Teva v. Eli Lilly (Fed. Cir., April 16, 2026) 2024-1094

This episode concerns an opinion in which the United States Court of Appeals for the Federal Circuit addresses a patent dispute between Teva Pharmaceuticals and Eli Lilly regarding treatments for headaches. The court reversed a lower court's judgment that had invalidated Teva’s patents, which cover the use of specific humanized antibodies to inhibit a protein associated with pain. While the district court initially ruled that the patents lacked sufficient written description and enablement, the appellate court found that Teva provided enough detail for a skilled artisan to understand and replicate the invention. The ruling emphasizes that because the antibodies and humanization techniqueswere already well-established in the field, the patents did not require exhaustive lists of every possible molecular variation. Ultimately, the court reinstated the jury's original verdict, which found that Eli Lilly had willfully infringed upon Teva’s valid patent claims.

This podcast is for entertainment purposes only and does not create an attorney-client relationship. The AI-generated hosts are not attorneys and are not providing legal advice. The choice of a lawyer is an important decision and should not be based solely upon advertisements.